美股新聞 標題聯播 · 近 24 小時 348 則 · 31 個來源 · 最新 9/20 04:16
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ARWR近 30 天 11 則 · 第 1 / 1 頁
- Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
- RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
- Arrowhead Achieves Clinical Validation for New Drug Platform
- FDA clears first generic radioligand drug; Sionna turns to layoffs
- Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026
- Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
- This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
- Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
- Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating?
- Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
- People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
- Top Midday Gainers
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。